Notice of Registration - Importers
2019 - Meridian Medical Technologies | Mylan Pharmaceuticals Inc. | Novitium Pharma LLC
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances Registration
[DRG No. 20-017]
ACTION: Notice of registration.
SUMMARY: The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule II controlled substances.
SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as an importers of various basic classes of schedule II controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for a hearing were submitted for these notices.
Company | FR Docket | Published |
---|---|---|
Meridian Medical Technologies | 84 FR 68473 | December 16, 2019 |
Mylan Pharmaceuticals Inc. | 84 FR 68474 | December 16, 2019 |
Novitium Pharma LLC | 84 FR 68474 | December 16, 2019 |
The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable various basic classes of schedule II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule II controlled substances to the above listed companies.
Dated: 2/10/2020
William T. McDermott,
Assistant Administrator.